Cardiorentis Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
6
Cardiorentis General Information
Description
Developer of natriuretic peptide drugs committed to bringing novel therapies to the treatment of heart failure and related cardiovascular diseases. The company specializes in developing ularitide used for acute heart failure along with a safety and efficacy study of an intravenous placebo-controlled randomized infusion of ularitide in a prospective double-blind study in patients with symptomatic and decompensated chronic heart failures, ensuring its clients with improved outcome benefits for patients with cardiovascular disease and medicines for diseases of high unmet medical need.
Contact Information
Website
www.cardiorentis.comCorporate Office
- Steinhauserstrasse 74
- 6300 Zug
- Switzerland
Corporate Office
- Steinhauserstrasse 74
- 6300 Zug
- Switzerland
Cardiorentis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cardiorentis Comparisons
Industry
Financing
Details
Cardiorentis Competitors (13)
One of Cardiorentis’s 13 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mesoblast | Corporation | Melbourne, Australia | ||||
| SanBio | Formerly VC-backed | Tokyo, Japan | ||||
| Orbsen Therapeutics | Formerly PE-Backed | Galway, Ireland | ||||
| Vivus | Corporate Backed or Acquired | Campbell, CA | ||||
| Cerenome | Corporation | Houston, TX |
Cardiorentis Patents
Cardiorentis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2014208851-A1 | A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications | Active | 25-Jan-2013 | ||
| AU-2014208851-B2 | A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications | Inactive | 25-Jan-2013 | ||
| WO-2014115033-A3 | A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications | Inactive | 25-Jan-2013 | ||
| EP-2948165-A2 | A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications | Inactive | 25-Jan-2013 | ||
| CA-2898571-A1 | Methods of treating cardiovascular indications | Inactive | 25-Jan-2013 | A61K38/2242 |
Cardiorentis Signals
Cardiorentis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cardiorentis FAQs
-
When was Cardiorentis founded?
Cardiorentis was founded in 2010.
-
Where is Cardiorentis headquartered?
Cardiorentis is headquartered in Zug, Switzerland.
-
What is the size of Cardiorentis?
Cardiorentis has 9 total employees.
-
What industry is Cardiorentis in?
Cardiorentis’s primary industry is Drug Discovery.
-
Is Cardiorentis a private or public company?
Cardiorentis is a Private company.
-
What is Cardiorentis’s current revenue?
The current revenue for Cardiorentis is .
-
How much funding has Cardiorentis raised over time?
Cardiorentis has raised $249M.
-
Who are Cardiorentis’s investors?
has invested in Cardiorentis.
-
Who are Cardiorentis’s competitors?
Mesoblast, SanBio, Orbsen Therapeutics, Vivus, and Cerenome are some of the 13 competitors of Cardiorentis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process